Therapeutic potential and safety of the combination of gabapentin and trazodone succinate (Trazapentine® tablets) for the control of feline idiopathic cystitis: from acute episodes to long-term prevention

The results of the conducted study demonstrate the high efficacy and safety of the unique combined drug Trazapentin® (gabapentin and succinate trazodone) on the market for the control of feline idiopathic cystitis and prevention of its relapses. Analysis of clinical data showed that its use for 7 days led to a significant reduction in symptom severity. Improvement in the general condition of cats was accompanied by a decrease in pain lev-els, cessation of vocalization, absence of hematuria, normalization of the frequency and quality of litter box visits, satisfactory bladder emptying, restoration of appetite and social activity. This indicates the multimodal effect of the drug on the psychoneuroendocrine status of animals suf-fering from idiopathic cystitis. The use of Trazapentin® for 180 days provided a stable positive preventive effect. The number of feline idiopathic cystitis cases in the experimental group decreased by 7 times com-pared to group of placebo, confirming its ability to prevent idiopathic cystitis relapses. Moreover, cats re-ceiving the drug showed a 41% reduction in the average duration of relapse episodes, which is a significant indicator of improved animal quality of life.